EcoDrugPlus

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSTRUG00000027060
Gene Symbol: EGLN1
1 Cross references
220 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSTRUG00000024714
Gene Symbol: EGLN3
3 Cross references
198 Possible Orthologues:

Endothelial Pas Domain-Containing Protein 1

Ensembl ID : ENSTRUG00000005627
Gene Symbol: LOC101067536
3 Cross references
212 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSTRUG00000012021
Gene Symbol: ECE1
1 Cross references
230 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSTRUG00000014468
Gene Symbol: EDNRA
3 Cross references
205 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSTRUG00000008869
Gene Symbol: EDNRB
4 Cross references
196 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSTRUG00000007046
Gene Symbol: EDNRB
1 Cross references
196 Possible Orthologues:

Endothelin Receptor Type B-Like

Ensembl ID : ENSTRUG00000017482
Gene Symbol: LOC101079790
3 Cross references
197 Possible Orthologues:

Ephrin Type-B Receptor 4-Like

Ensembl ID : ENSTRUG00000028576
Gene Symbol: LOC101074460
3 Cross references
168 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSTRUG00000011834
Gene Symbol: EGFR
3 Cross references
212 Possible Orthologues:

Epoxide Hydrolase 2

Ensembl ID : ENSTRUG00000011454
Gene Symbol: EPHX2
2 Cross references
203 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSTRUG00000028982
Gene Symbol: ERBB2
1 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).